Exploiting apoptosis pathways for the treatment of pediatric cancers

Pediatric Blood and Cancer

Volumn 53, Issue 4, 2009, Pages 533-536

  Fulda, Simone ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Apoptosis; Bcl 2; IAPs; Pediatric cancers; TRAIL

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ABT 263; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; ANTISENSE OLIGONUCLEOTIDE G3139; APOPTOSIS INHIBITOR; CASPASE 3; CASPASE 7; CASPASE 9; CYCLOPHOSPHAMIDE; CYTOCHROME C; DEATH RECEPTOR; DOXORUBICIN; OBLIMERSEN; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN BID; PROTEIN MCL 1; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; SURVIVIN; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; INHIBITOR OF APOPTOSIS PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL CULTURE; CANCER RELAPSE; CANCER RESISTANCE; CARCINOGENESIS; CELL PERMEABILIZATION; CHILD; CHILDHOOD CANCER; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA; LEUKEMIA REMISSION; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHABDOMYOSARCOMA; SIGNAL TRANSDUCTION; NEOPLASM; PATHOLOGY; PHYSIOLOGY;

APOPTOSIS; CHILD; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 69849092354     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21922     Document Type: Review

References (47)

1. Hengartner MO. The biochemistry of apoptosis. Nature 2000;407:770-776.
2. Evan GI, Vousden KH. Proliferation, cell cycle, and apoptosis in cancer. Nature 2001;411:342-348. (Pubitemid 32467043)
3. Lowe SW, Lin AW. Apoptosis in cancer. Carcinogenesis 2000;21:485-495.
4. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
5. Troeger A, Siepermann M, Escherich G, et al. Survivin and its prognostic significance in pediatric acute B-cell precursor lymphoblastic leukemia. Haematologica 2007;92:1043-1050. (Pubitemid 350144210)
6. Degterev A, Boyce M, Yuan J. A decade of caspases. Oncogene 2003;22:8543-8567.
7. Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006;25:4798-4811. (Pubitemid 44187627)
8. Walczak H, Krammer PH. The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. Exp Cell Res 2000;256:58-66. (Pubitemid 30211167)
9. Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007;26:1324-1337. (Pubitemid 46328466)
10. Saelens X, Festjens N, Vande Walle L, et al. Toxic proteins released from mitochondria in cell death. Oncogene 2004;23:2861-2874. (Pubitemid 38638848)
11. Okada H, Mak TW. Pathways of apoptotic and non-apoptotic death in tumour cells. Nat Rev Cancer 2004;4:592-603. (Pubitemid 39025054)
12. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: A link between cancer genetics and chemotherapy. Cell 2002;108:153-164.
13. Ashkenazi A. Targeting the extrinsic apoptosis pathway in cancer. Cytokine Growth Factor Rev 2008;19:325-331.
14. Yang X, Thiele CJ. Targeting the tumor necrosis factor-related apoptosis-inducing ligand path in neuroblastoma. Cancer Lett 2003;197:137-143. (Pubitemid 36860003)
15. Fulda S, Meyer E, Debatin KM. Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Oncogene 2002;21:2283-2294. (Pubitemid 34407288)
16. Petak I, Douglas L, Tillman DM, et al. Pediatric rhabdomyosarcoma cell lines are resistant to Fas-induced apoptosis and highly sensitive to TRAIL-induced apoptosis. Clin Cancer Res 2000;6:4119-4127. (Pubitemid 30807108)
17. Ehrhardt H, Fulda S, Schmid I, et al. TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-kappaB. Oncogene 2003;22:3842-3852. (Pubitemid 36819657)
18. Van Valen F, Fulda S, Truckenbrod B, et al. Apoptotic responsiveness of the Ewing's sarcoma family of tumours to tumour necrosis factor-related apoptosis-inducing ligand (TRAIL). Int J Cancer 2000;88:252-259. (Pubitemid 30745220)
19. Kontny HU, Hammerle K, Klein R, et al. Sensitivity of Ewing's sarcoma to TRAIL-induced apoptosis. Cell Death Differ 2001;8:506-514. (Pubitemid 32492771)
20. Fulda S. Targeting inhibitor of apoptosis proteins (IAPs) for cancer therapy. Anticancer Agents Med Chem 2008;8:533-539.
21. Ashkenazi A, Herbst RS. To kill a tumor cell: The potential of proapoptotic receptor agonists. J Clin Invest 2008;118:1979-1990. (Pubitemid 351872316)
22. Humphreys RC, Halpern W. Trail receptors: Targets for cancer therapy. Adv Exp Med Biol 2008;615:127-158.
23. Fulda S, Wick W, Weller M, et al. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med 2002;8:808-815. (Pubitemid 34887244)
24. Dole M, Nunez G, Merchant AK, et al. Bcl-2 inhibits chemotherapy-induced apoptosis in neuroblastoma. Cancer Res 1994;54:3253-3259. (Pubitemid 24208938)
25. Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005;435:677-681. (Pubitemid 40825512)
26. Kang MH, Kang YH, Szymanska B, et al. Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo. Blood 2007;110:2057-2066.
27. Lock R, Carol H, Houghton PJ, et al. Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program. Pediatr Blood Cancer 2008;50:1181-1189. (Pubitemid 351555542)
28. Goldsmith KC, Liu X, Dam V, et al. BH3 peptidomimetics potently activate apoptosis and demonstrate single agent efficacy in neuroblastoma. Oncogene 2006;25:4525-4533. (Pubitemid 44175112)
29. Rheingold SR, Hogarty MD, Blaney SM, et al. Phase I Trial of G3139, a Bcl-2 antisense oligonucleotide, combined with doxorubicin and cyclophosphamide in children with relapsed solid tumors: A children's oncology group study. J Clin Oncol 2007;25:1512-1518.
30. Salvesen GS, Duckett CS. IAP proteins: Blocking the road to death's door. Nat Rev Mol Cell Biol 2002;3:401-410.
31. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003;3:46-54. (Pubitemid 37328886)
32. Islam A, Kageyama H, Takada N, et al. High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene 2000;19:617-623. (Pubitemid 30102912)
33. Adida C, Berrebi D, Peuchmaur M, et al. Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet 1998;351:882-883. (Pubitemid 28121185)
34. Azuhata T, Scott D, Takamizawa S, et al. The inhibitor of apoptosis protein survivin is associated with high-risk behavior of neuroblastoma. J Pediatr Surg 2001;36:1785-1791. (Pubitemid 33131683)
35. Ito R, Asami S, Motohashi S, et al. Significance of survivin mRNA expression in prognosis of neuroblastoma. Biol Pharm Bull 2005;28:565-568. (Pubitemid 40879915)
36. Miller MA, Ohashi K, Zhu X, et al. Survivin mRNA levels are associated with biology of disease and patient survival in neuroblastoma: A report from the children's oncology group. J Pediatr Hematol Oncol 2006;28:412-417. (Pubitemid 44114547)
37. Troger A, Siepermann M, Mahotka C, et al. Role of survivin splice variants in pediatric acute precursor B lymphoblastic leukemia. Klin Padiatr 2007;219:127-133. (Pubitemid 46983774)
38. Shiozaki EN, Shi Y. Caspases, IAPs and Smac/DIABLO: Mechanisms from structural biology. Trends Biochem Sci 2004;29:486-494.
39. Giagkousiklidis S, Vogler M, Westhoff MA, et al. Sensitization for gamma-irradiation-induced apoptosis by second mitochondria-derived activator of caspase. Cancer Res 2005;65:10502-10513. (Pubitemid 41743746)
40. Vogler M, Giagkousiklidis S, Genze F, et al. Inhibition of clonogenic tumor growth: A novel function of Smac contributing to its antitumor activity. Oncogene 2005;24:7190-7202. (Pubitemid 41679281)
41. LaCasse EC, Kandimalla ER, Winocour P, et al. Application of XIAP antisense to cancer and other proliferative disorders: Development of AEG35156/GEM640. Ann NY Acad Sci 2005;1058:215-234.
42. LaCasse EC, Cherton-Horvat GG, Hewitt KE, et al. Preclinical characterization of AEG35156/GEM 640, a second-generation antisense oligonucleotide targeting X-linked inhibitor of apoptosis. Clin Cancer Res 2006;12:5231-5241.
43. Jolivet J, Dean E, Ward T, et al. Aphase I trial of AEG35156 (XIAP antisense) administered as 2-hour intravenous infusions in patients with advanced tumours. J Clin Oncol (Meeting Abstr) 2008;26:3541.
44. Kim S, Kang J, Qiao J, et al. Phosphatidylinositol 3-kinase inhibition down-regulates survivin and facilitates TRAIL-mediated apoptosis in neuroblastomas. J Pediatr Surg 2004;39:516-5521. (Pubitemid 38500368)
45. Schultze K, Bock B, Eckert A, et al. Troglitazone sensitizes tumor cells to TRAIL-induced apoptosis via down-regulation of FLIP and Survivin. Apoptosis 2006;11:1503-1512. (Pubitemid 44253668)
46. Fulda S, Debatin KM. Sensitization for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by the chemopreventive agent resveratrol. Cancer Res 2004;64:337-346. (Pubitemid 38114116)
47. Shankar SL, Mani S, O'Guin KN, et al. Survivin inhibition induces human neural tumor cell death through caspase-independent and -dependent pathways. J Neurochem 2001;79:426-436. (Pubitemid 32988959)